Jasmine Andrade [ad_1]
Nicox Offers Fourth Quarter 2021 Business and Financial Highlights
- 
- Mont Blanc Phase 3 clinical demo of NCX 470 in glaucoma progressing fast with recruitmentnow at 90%
- VYZULTA® and ZERVIATE® fourth quarter U.S. prescriptions amplified by 39% and 129%, respectively, in 2021 vs.2020
- 
- Web profits of €3.5 million in the fourth quarter of 2021, €7.2 million for 2021 income of €41.9million onDecember 31, 2021





January 21, 2022 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an worldwide ophthalmology corporation, offered business and financial highlights for fourth quarter 2021 for Nicox SA and its subsidiaries (the “Nicox Group”) as nicely as important expected worth-inflection milestones today.
Fourth Quarter 2021 Economical Highlights
As of December 31, 2021, the Nicox Team had money and cash equivalents of €41.9 million as in comparison with €32.7 million at September 30, 2021 and €47.2 million at December 31, 2020. The Business is financed till fourth quarter 2023, financing improvement of NCX 470 only. Web profits1 for the fourth quarter of 2021 was €3.5 million (€0.5 million of net royalty payments, €3. million non-funds accounting adjustment originally recorded as deferred cash flow next a licensing payment acquired from Ocumension in March 2020). Web revenue1 for the fourth quarter of 2020 was €5.8 million (€0.3 million royalty payments, €5.5 million license payments).
Fourth quarter income for VYZULTA in 2021 was impacted by more rebates owing to yr-conclude correct-up calculations. In addition, Accessibility and Medicare Component D coverage for VYZULTA expanded in 2021, which raises the amount of rebates. In spite of this, prescriptions for VYZULTA grew by 32% in 2021 in comparison to 2020. We feel the enhanced obtain will greater placement VYZULTA for advancement.
As of December 31, 2021, the Nicox Team experienced economical financial debt of €18.3 million consisting of €16.3 million in the kind of a bond funding agreement with Kreos Funds signed in January 2019 and a €2. million credit score arrangement assured by the French Condition in August 2020 in the context of the…
[ad_2]
Examine additional below
